University of Southern California

University of Miami

The United States of America, as Represented by the Secretary, Department of Health and Human Services

University of Oregon

State of Oregon

Jonathan Cheng

Peter A Jones

Gangning Liang

Victor E Marquez

Sheldon B Greer

Eric U Selker

Cindy B Matsen

Isabel D C Markl

Hualin Fu

Zebularine has hypomethylating activity, and can be used to inhibit, reverse, and/or reduce DNA methylation in vivo and in vitro. Methods are provided for treating methylation-linked conditions through the application of 2-pyrimidinone derivatives, such as Zebularine. Compositions, including pharmaceutical compositions, comprising such derivatives are also provided. Also provided are kits for use in inhibiting DNA methylation, which kits include an amount of a 2-pyrimidinone derivative.

Inhibitor of DNA methylation

There is disclosed 103 novel methylation-altered DNA sequences ('marker sequences') that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.

Methylation altered DNA sequences as markers associated with human cancer

Growing community of inventors

Alhambra, CA, United States of America

Jonathan Cheng